Clinical Trials Directory

We are doing this study to find out if filling the uterus with a soft, experimental material called Juveena Hydrogel (the study product) at the end of gynecological surgical procedures can safely and effectively reduce the formation or reformation of intrauterine adhesions. The device is referred to as a "hydrogel" because it is made of approximately 90% water. The other main ingredient is polyethylene glycol, or "PEG," a material that is widely used in the preparation of drugs and other medical products. The study product will gradually break down over time (within approximately 2 to 3 weeks), so no other procedure is needed to remove it.

We are doing this study to find out if an experimental drug called KTX-1001 (the study drug) is a safe and effective treatment for multiple myeloma. We want to identify the most appropriate dose and dosing schedule of the study drug for patients with multiple myeloma.

We are doing this study to find the most effective, safe dose of an experimental drug called selinexor (the study drug). We want to know how well this study drug works in people with myelofibrosis when it is given in combination with a drug called ruxolitinib.

We are doing this study to find the most effective, safe dose of an experimental drug called selinexor (the study drug) for people with myelofibrosis (MF).

We are doing this study to compare a ketogenic diet (a diet with high fat, moderate protein, very low carbohydrate) versus a normal diet. We want to find out if it has any effect on survival time for people with glioblastoma multiforme (GBM). We also want to know how biomarkers change when people follow a ketogenic diet. A biomarker is a biological molecule found in blood, other body fluids, or tissues. Biomarkers may be a sign of a condition or disease and can be used to predict someone's response to a specific treatment.

We are doing this study to find out if an experimental drug called KPG-818 (the study drug) is a safe and effective treatment for various hematological malignancies. The study drug will be combined with dexamethasone for participants who have multiple myeloma.

This is a research study to see if two doses (low and high) of the KPI-012 eye drops are safe and work to repair persistent corneal epithelial defects (PCED), a non-healing corneal wound that does not heal with standard treatments, compared to the placebo (eye drops without any active ingredients).

We are doing this study to find the most effective, safe dose of an experimental drug called ziftomenib (the study drug). We want to know how well this study drug works in people with AML that have certain mutations in the NPM1 gene and rearrangements involving the KMT2A gene when it is given alone or in combination with other cancer drugs.